Genistein induces G2/M cell cycle arrest and apoptosis via ATM/p53-dependent pathway in human colon cancer cells

International Journal of Oncology

Volumn 43, Issue 1, 2013, Pages 289-296

  Zhang, Zhiyu ^a,b   Wang, Chong Zhi ^a,b   Du, Guang Jian ^a,b   Qi, Lian Wen ^a,b   Calway, Tyler ^b   He, Tong Chuan ^b   Du, Wei ^c   Yuan, Chun Su ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer chemoprevention; Colon cancer; G2 M cell cycle arrest; Isoflavones; p53

Indexed keywords

ATM PROTEIN; BIOCHANIN A; DAIDZEIN; GENISTEIN; PROTEIN P21; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE G2 PHASE; COLON CANCER; CONTROLLED STUDY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SOYBEAN;

APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL CYCLE CHECKPOINTS; COLONIC NEOPLASMS; G2 PHASE CELL CYCLE CHECKPOINTS; GENE REGULATORY NETWORKS; GENISTEIN; HCT116 CELLS; HUMANS; ISOFLAVONES; RHO GTP-BINDING PROTEINS; SOYBEANS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84879641544     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1946     Document Type: Article

References (39)

1. Arber N and Levin B: Chemoprevention of colorectal cancer: ready for routine use? Recent Results Cancer Res 166: 213-230, 2005.
2. Rodriguez M, Du GJ, Wang CZ and Yuan CS: Letter to the editor: Panaxadiol's anticancer activity is enhanced by epicatechin. Am J Chin Med 38: 1233-1235, 2010.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
4. Wils J, O'Dwyer P and Labianca R: Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. Ann Oncol 12: 13-22, 2001. (Pubitemid 32162443)
5. Segal NH and Saltz LB: Evolving treatment of advanced colon cancer. Annu Rev Med 60: 207-219, 2009.
6. Thomasset SC, Berry DP, Garcea G, Marczylo T, Steward WP and Gescher AJ: Dietary polyphenolic phytochemicals - promising cancer chemopreventive agents in humans? A review of their clinical properties. Int J Cancer 120: 451-458, 2007. (Pubitemid 44969013)
7. Doll R and Peto R: The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66: 1191-1308, 1981. (Pubitemid 11063920)
8. Umthong S, Puthong S and Chanchao C: Trigona laeviceps propolis from Thailand: antimicrobial, antiproliferative and cytotoxic activities. Am J Chin Med 37: 855-865, 2009.
9. Fournier DB, Erdman JW Jr and Gordon GB: Soy, its components and cancer prevention: a review of the in vitro, animal and human data. Cancer Epidemiol Biomarkers Prev 7: 1055-1065, 1998. (Pubitemid 28514109)
10. Kao TH, Chien JT and Chen BH: Extraction yield of isoflavones from soybean cake as affected by sovlent and supercritical carbon dioxide. Food Chem 107: 1728-1736, 2008.
11. Banerjee S, Li Y, Wang Z and Sarkar FH: Multi-targeted therapy of cancer by genistein. Cancer Lett 269: 226-242, 2008.
12. Hartwell LH and Kastan MB: Cell cycle control and cancer. Science 266: 1821-1828, 1994.
13. Igney FH and Krammer PH: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2: 277-288, 2002. (Pubitemid 37328781)
14. Agarwal MK, Hastak K, Jackson MW, Breit SN, Stark GR and Agarwal ML: Macrophage inhibitory cytokine 1 mediates a p53-dependent protective arrest in S phase in response to starvation for DNA precursors. Proc Natl Acad Sci USA 103: 16278-16283, 2006. (Pubitemid 44715187)
15. Liu BP, Chong EY, Cheung FW, Duan JA, Che CT and Liu WK: Tangutorine induces p21 expression and abnormal mitosis in human colon cancer HT-29 cells. Biochem Pharmacol 70: 287-299, 2005. (Pubitemid 40814410)
16. Taylor CK, Levy RM, Elliott JC and Burnett BP: The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical and clinical studies. Nutr Rev 67: 398-415, 2009.
17. Schleipen B, Hertrampf T, Fritzemeier KH, et al: ERbeta-specific agonists and genistein inhibit proliferation and induce apoptosis in the large and small intestine. Carcinogenesis 32: 1675-1683, 2011.
18. Vousden KH and Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283, 2007. (Pubitemid 46474662)
19. Luo X, Chen J, Song WX, et al: Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest 88: 1264-1277, 2008.
20. Kim EJ, Shin HK and Park JH: Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of Genistein. J Med Food 8: 431-438, 2005. (Pubitemid 43121893)
21. Meloche S and Pouyssegur J: The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26: 3227-3239, 2007. (Pubitemid 46763017)
22. Yu ZL, Li WJ and Liu FY: Inhibition of proliferation and induction of apoptosis by genistein in colon cancer HT-29 cells. Cancer Lett 215: 159-166, 2004.
23. Park JH, Oh EJ, Choi YH, et al: Synergistic effects of dexamethasone and genistein on the expression of Cdk inhibitor p21(WAF1/CIP1) in human hepatocellular and colorectal carcinoma cells. Int J Oncol 18: 997-1002, 2001.
24. Vousden KH and Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604, 2002. (Pubitemid 37328926)
25. Qi W, Weber CR, Wasland K and Savkovic SD: Genistein inhibits proliferation of colon cancer cells by attenuating a negative effect of epidermal growth factor on tumor suppressor FOXO3 activity. BMC Cancer 11: 219, 2011.
26. Zhou BB and Elledge SJ: The DNA damage response: putting checkpoints in perspective. Nature 408: 433-439, 2000.
27. Schar P: Spontaneous DNA damage, genome instability and cancer - when DNA replication escapes control. Cell 104: 329-332, 2001.
28. Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature 411: 366-374, 2001.
29. Rouse J and Jackson SP: Interfaces between the detection, signaling and repair of DNA damage. Science 297: 547-551, 2002. (Pubitemid 34815330)
30. Lee SW, Fang L, Igarashi M, Ouchi T, Lu KP and Aaronson SA: Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53. Proc Natl Acad Sci USA 97: 8302-8305, 2000. (Pubitemid 30639667)
31. Tang J and Chu G: Xeroderma pigmentosum complementation group E and UV-damaged DNA-binding protein. DNA Repair 1: 601-616, 2002. (Pubitemid 34765611)
32. Levine AJ and Oren M: The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9: 749-758, 2009.
33. Toledo F and Wahl GM: Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6: 909-923, 2006. (Pubitemid 44862676)
34. Riley T, Sontag E, Chen P and Levine A: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9: 402-412, 2008. (Pubitemid 351574202)
35. Chen Z, Trotman LC, Shaffer D, et al: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725-730, 2005. (Pubitemid 41117277)
36. Fridman JS and Lowe SW: Control of apoptosis by p53. Oncogene 22: 9030-9040, 2003. (Pubitemid 38121703)
37. Hoglund P: DNA damage and tumor surveillance: one trigger for two pathways. Sci STKE 2006: pe2, 2006.
38. Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320, 2005. (Pubitemid 41130944)
39. Abraham RT: Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15: 2177-2196, 2001. Complementary and Alternative Medicine Complementary and Alternative Medicine